SeekingAlpha · Sep 27, 2026
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon bets on functional outcomes in geographic atrophy & GBS; ARCHER II vision endpoints read out in Q4 2026. Click for more on ANNX stock.
AN
NASDAQ · ANNX
Annexon, Inc.
Healthcare · Biotechnology
$4.20
Down-$0.17 (-4.05%)
Updated Oct 6, 2026, 9:53 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 669.73M
- P/E ratio
- -4.03
- Dividend yield
- 0.00%
- 52-week range
- $3.63 – $6.62
- Volume
- 3.45M
- Avg. volume
- 2.57M
Price performance · ANNX
ANNX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ANNX closed at $4.20 after 20 trading sessions, down 10.06% for the selected period.
- Last close
- $4.20
- Period change
- -10.06%
- Period low
- $3.64
- Period high
- $4.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.25 | $4.31 | $4.06 | $4.20 | 3.45M |
| Oct 2, 2026 | $4.21 | $4.265 | $4.105 | $4.19 | 4.02M |
| Oct 1, 2026 | $4.18 | $4.38 | $4.12 | $4.12 | 3.92M |
| Sep 30, 2026 | $4.19 | $4.27 | $4.05 | $4.23 | 4.41M |
| Sep 29, 2026 | $4.00 | $4.2372 | $3.94 | $4.13 | 3.71M |
| Sep 28, 2026 | $3.85 | $4.08 | $3.735 | $4.01 | 5.07M |
| Sep 25, 2026 | $3.81 | $3.85 | $3.63 | $3.64 | 3.51M |
| Sep 24, 2026 | $3.85 | $3.87 | $3.725 | $3.80 | 2.02M |
| Sep 23, 2026 | $4.18 | $4.19 | $3.81 | $3.87 | 2.42M |
| Sep 22, 2026 | $4.28 | $4.34 | $4.13 | $4.18 | 2M |
| Sep 21, 2026 | $4.27 | $4.358 | $4.12 | $4.22 | 4.19M |
| Sep 18, 2026 | $4.16 | $4.31 | $4.13 | $4.23 | 4.94M |
| Sep 17, 2026 | $3.922 | $4.22 | $3.915 | $4.17 | 3.12M |
| Sep 16, 2026 | $3.91 | $4.00 | $3.875 | $3.93 | 4.52M |
| Sep 15, 2026 | $3.93 | $3.975 | $3.79 | $3.92 | 2.96M |
| Sep 14, 2026 | $3.97 | $4.035 | $3.88 | $3.95 | 2.9M |
| Sep 11, 2026 | $4.195 | $4.195 | $3.92 | $3.94 | 3.94M |
| Sep 10, 2026 | $4.33 | $4.33 | $4.04 | $4.14 | 4.2M |
| Sep 9, 2026 | $4.60 | $4.66 | $4.34 | $4.37 | 5.53M |
| Sep 8, 2026 | $4.76 | $4.785 | $4.64 | $4.67 | 2.14M |
Latest ANNX news
The latest Smart Investors Daily articles mentioning ANNX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ANNX research
Overview
Company profile and research snapshot.
Company profile
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | JP Morgan | Overweight | — |
| Sep 1, 2026 | JP Morgan | Overweight | — |
| Aug 13, 2026 | Citizens | Market Perform | — |
| Jul 21, 2026 | Citizens | Market Underperform | — |
| Jul 15, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 24, 2026
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immuno
Yahoo · Sep 16, 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule
SeekingAlpha · Sep 4, 2026
Annexon, Inc. (ANNX) Virtual Business Update Call Transcript
Annexon (ANNX) Virtual Business Update Call recap: Phase III updates for GBS and geographic atrophy, r
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
